Summary & Overview
HCPCS S0160: Dextroamphetamine Sulfate, 5 mg
HCPCS Level II code S0160 denotes a 5 mg formulation of dextroamphetamine sulfate, an oral stimulant commonly prescribed for attention-deficit/hyperactivity disorder and some sleep disorders. Nationally, accurate coding for drug-specific HCPCS Level II codes supports consistent billing, pharmacy reimbursement, and utilization tracking for controlled stimulant medications. This code matters for payers and providers because it identifies a specific product strength that can affect coverage decisions, prior authorization pathways, and pharmacy dispensing workflows.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on the clinical context of S0160, typical sites of service where the medication is dispensed, and the practical implications for claims processing and pharmacy billing. The publication also outlines common modifiers associated with HCPCS billing when available and notes where input data are missing.
The analysis provides benchmarks and policy-relevant points for coding and reimbursement administrators, pharmacy billing staff, and clinical managers responsible for controlled substance prescribing. Data not provided in the input—such as specific payer policies, taxonomies, ICD-10 pairings, or related codes—are identified as unavailable.
Billing Code Overview
HCPCS Level II code S0160 represents Dextroamphetamine sulfate, 5 mg. This code describes a specific oral stimulant medication formulation used in the treatment of attention-deficit/hyperactivity disorder (ADHD) and certain narcolepsy cases.
-
Service type: Prescription drug dispensing of a 5 mg dextroamphetamine sulfate tablet
-
Typical site of service: Outpatient pharmacy or clinic-based medication dispensing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 12-year-old patient presents to a pediatric primary care clinic with a 6-month history of inattention, difficulty completing schoolwork, and impulsive behavior. The clinician performs a diagnostic evaluation for attention-deficit/hyperactivity disorder (ADHD), documents symptom onset, school/parent reports, and past medical history, and decides to initiate stimulant pharmacotherapy. The clinic dispenses a sample or arranges immediate pharmacy delivery of S0160 (Dextroamphetamine sulfate, 5 mg) for a short trial to assess tolerability and initial response. The typical workflow includes medication counseling on dosing, side effects, and safety; documentation of informed consent and monitoring plan; scheduling follow-up within 2–4 weeks to assess effectiveness and adverse effects; and updating the problem list and medication record in the electronic health record.
Typical site of service is an outpatient clinic (pediatric or psychiatric office) or an outpatient pharmacy coordinating medication supply. The patient encounter is commonly performed by a pediatrician, child and adolescent psychiatrist, or developmental-behavioral pediatrician; pharmacologic management may involve a clinical pharmacist for counseling and dispensing coordination.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; not recommended for reporting specific circumstances |